AI-Driven, Blockchain-Secured Cancer Treatment System

Publication ID: 24-11857601_0008_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “AI-Driven, Blockchain-Secured Cancer Treatment System,” Published Technical Disclosure No. 24-11857601_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857601_0008_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,601.

Summary of the Inventive Concept

A novel cancer treatment system integrating a pharmaceutical composition comprising a fusion protein dimer and an anticancer agent with AI-driven personalized treatment plans, blockchain-secured storage, and IoT-enabled health monitoring.

Background and Problem Solved

The original patent disclosed a pharmaceutical composition for cancer treatment, but its efficacy and accessibility were limited by the lack of personalized treatment approaches, inadequate data security, and insufficient patient monitoring. The new inventive concept addresses these limitations by synergistically combining the patented composition with AI, blockchain, and IoT technologies.

Detailed Description of the Inventive Concept

The system comprises a pharmaceutical composition including a fusion protein dimer and an anticancer agent, which is administered in conjunction with a personalized AI-driven treatment plan generated based on a patient's genomic profile. The pharmaceutical composition is stored in a blockchain-secured, decentralized storage system, ensuring secure and transparent access to authorized healthcare professionals. A wearable IoT device tracks the patient's vital signs and health metrics, which are analyzed by a cloud-based server to optimize treatment efficacy. The system enables the creation of personalized cancer treatment models using digital twins and AI simulations, allowing for optimal treatment plan selection.

Novelty and Inventive Step

The new inventive concept introduces the synergistic combination of AI-driven personalized treatment plans, blockchain-secured storage, and IoT-enabled health monitoring with the patented pharmaceutical composition, providing a non-obvious and innovative solution for cancer treatment.

Alternative Embodiments and Variations

Alternative embodiments may include the use of different AI algorithms, blockchain protocols, or IoT devices. Variations may involve the integration of additional technologies, such as new materials or robotics, to further enhance the system's efficacy and accessibility.

Potential Commercial Applications and Market

The AI-driven, blockchain-secured cancer treatment system has significant commercial potential in the pharmaceutical and healthcare industries, offering a competitive advantage in personalized cancer treatment and data security. Target markets include hospitals, research institutions, and pharmaceutical companies.

CPC Classifications

Section	Class	Group
A	A61	A61K38/2013
A	A61	A61K31/337
A	A61	A61K31/444
A	A61	A61K31/4439
A	A61	A61K31/47
A	A61	A61K31/4709
A	A61	A61K31/502
A	A61	A61K31/506
A	A61	A61K31/5025
A	A61	A61K31/519
A	A61	A61K31/708
A	A61	A61K33/243
A	A61	A61K38/1774
A	A61	A61K39/3955
A	A61	A61K45/06
A	A61	A61P35/00

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical biotechnology, specifically cancer treatment technologies involving fusion proteins, targeted drug delivery, and personalized medicine systems with a focus on immunotherapeutic approaches

Person of Ordinary Skill (PHOSITA) Profile

A person with advanced degrees in biotechnology, molecular biology, or pharmaceutical sciences, with expertise in protein engineering, cancer treatment methodologies, and interdisciplinary medical technology integration

Obviousness Rationale

A PHOSITA would recognize that integrating AI-driven personalization, blockchain security, and IoT monitoring with the existing fusion protein cancer treatment represents a predictable technological extension leveraging known digital health technologies. The core pharmaceutical composition remains substantially unchanged from the source patent, with the added technological infrastructure representing standard evolutionary approaches in personalized medicine. The systematic combination of existing technologies to enhance treatment delivery and monitoring would be considered an obvious optimization strategy by a skilled practitioner.

Obvious Combinations & Variations

Source Patent Element

Fusion protein dimer comprising CD80 fragment and IL-2 variant for cancer treatment

PTD Variation

Adding AI-driven personalized treatment plan generation based on patient genomic profile

Obviousness Reasoning

Personalized medicine approaches using genomic profiling are well-established techniques for optimizing cancer treatment, representing a predictable application of known precision medicine methodologies

Source Patent Element

Pharmaceutical composition with anticancer agents

PTD Variation

Blockchain-secured storage and access for pharmaceutical composition

Obviousness Reasoning

Secure digital storage and controlled access for medical information is a standard technological solution in healthcare information management, representing an obvious implementation of existing cybersecurity practices

Source Patent Element

Cancer treatment pharmaceutical composition

PTD Variation

IoT-enabled health monitoring and real-time treatment efficacy tracking

Obviousness Reasoning

Remote patient monitoring using wearable technologies is a known technique in modern medical practice, providing predictable benefits for treatment optimization and patient management

Source Patent Element

Fusion protein cancer treatment methodology

PTD Variation

Digital twin simulation for treatment scenario planning

Obviousness Reasoning

Computational modeling of medical treatments using AI is an established approach in precision medicine, representing a logical extension of existing simulation and predictive technologies

Source Patent Element

Anticancer pharmaceutical composition

PTD Variation

Cloud-based server for analyzing patient health data and treatment optimization

Obviousness Reasoning

Cloud computing and data analysis for medical treatment refinement are standard technological approaches in contemporary healthcare technology integration

35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in this Published Technical Disclosure would be considered obvious to a Person Having Ordinary Skill In The Art based on the teachings of US Patent 11857601, as the technological integrations represent predictable combinations of known techniques in personalized medicine, digital health monitoring, and treatment optimization, without requiring inventive complexity beyond the capabilities of an ordinarily skilled practitioner in the field.

Original Patent Information

Patent Number	US 11,857,601
Title	Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug
Assignee(s)	GI Innovation, Inc.